Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of clear and sunny skies hovering over the Pharmalot campus, which has settled down now that the short person has left for the local schoolhouse. This leaves us to engage in our usual rituals. You know the drill — we are firing up the coffee kettle for a cup of stimulation and getting our to-do list in order. Never a day goes by without a to-do list, yes? So time to get cracking. Here are some tidbits to help you on your own journey. Hope today is successful and do keep in touch…

Researchers have started to recruit healthy Seattle-area volunteers to participate in the first clinical trial of an experimental coronavirus vaccine, a faster-than-expected start for the first vaccine readied for testing, The Wall Street Journal notes. Kaiser Permanente Washington Health Research Institute in Seattle said Wednesday it aims to enroll 45 adults from the region in the trial. The study will test the safety of various doses of the vaccine developed by Moderna (MRNA) and whether the shots produce an immune response.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy